183 related articles for article (PubMed ID: 25301489)
1. Overexpression of prothymosin alpha is related to pituitary adenoma recurrence but not to adenoma invasiveness and proliferation.
Pawlikowski M; Radek M; Kunert-Radek J; Jaranowska M; Świętosławski J; Winczyk K
Endokrynol Pol; 2014; 65(5):382-6. PubMed ID: 25301489
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of prothymosin alpha in pituitary adenomas--a new marker of tumor recurrence?
Pawlikowski M; Winczyk K
Folia Histochem Cytobiol; 2009; 47(4):559-62. PubMed ID: 20430720
[TBL] [Abstract][Full Text] [Related]
3. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
4. Expression of follicle stimulating hormone receptors in pituitary adenomas - a marker of tumour aggressiveness?
Pawlikowski M; Radek M; Jaranowska M; Kunert-Radek J; Swietoslawski J; Winczyk K
Endokrynol Pol; 2014; 65(6):469-71. PubMed ID: 25554615
[TBL] [Abstract][Full Text] [Related]
5. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.
Shimon I; Hinton DR; Weiss MH; Melmed S
Clin Endocrinol (Oxf); 1998 Jan; 48(1):23-9. PubMed ID: 9509064
[TBL] [Abstract][Full Text] [Related]
6. PTTG and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Przegl Lek; 2016; 73(2):53-8. PubMed ID: 27197423
[TBL] [Abstract][Full Text] [Related]
7. High Ki-67 expression is associated with prolactin secreting pituitary adenomas.
Bălinişteanu B; Cîmpean AM; Ceauşu AR; Corlan AS; Melnic E; Raica M
Bosn J Basic Med Sci; 2017 May; 17(2):104-108. PubMed ID: 28432860
[TBL] [Abstract][Full Text] [Related]
8. Plurihormonality of pituitary adenomas in light of immunohistochemical studies.
Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2010; 61(1):63-6. PubMed ID: 20205106
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and growth fractions of pituitary adenomas.
Yonezawa K; Tamaki N; Kokunai T
Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815
[TBL] [Abstract][Full Text] [Related]
10. "Silent" thyrotropin (TSH) expression in acromegaly and clinically non-functioning pituitary adenomas.
Pawlikowski M; Pisarek H; Jaranowska M; Radek M; Winczyk K; Kunert-Radek J
Endokrynol Pol; 2016; 67(5):515-518. PubMed ID: 27403655
[TBL] [Abstract][Full Text] [Related]
11. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
13. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
14. Prothymosin-alpha and Ki-67 expression in pituitary adenomas.
Wierzbicka-Tutka I; Sokołowski G; Bałdys-Waligórska A; Adamek D; Radwańska E; Gołkowski F
Postepy Hig Med Dosw (Online); 2016 Nov; 70(0):1117-1123. PubMed ID: 27892895
[TBL] [Abstract][Full Text] [Related]
15. Cell proliferation parameters and apoptosis indices in pituitary macroadenomas.
Ruggeri RM; Costa G; Simone A; Campennì A; Sindoni A; Ieni A; Cavallari V; Trimarchi F; Curtò L
J Endocrinol Invest; 2012 May; 35(5):473-8. PubMed ID: 21897111
[TBL] [Abstract][Full Text] [Related]
16. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of FSH receptors in pituitary adenomas and adrenal tumors.
Pawlikowski M; Pisarek H; Kubiak R; Jaranowska M; Stępień H
Folia Histochem Cytobiol; 2012 Oct; 50(3):325-30. PubMed ID: 23042261
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas.
Mastronardi L; Guiducci A; Puzzilli F
BMC Cancer; 2001; 1():12. PubMed ID: 11570981
[TBL] [Abstract][Full Text] [Related]
19. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
Lath R; Chacko G; Chandy MJ
Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
[TBL] [Abstract][Full Text] [Related]
20. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
